Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kunhwa KimAbhishek MaitiSanam LoghaviRasoul PourebrahimTapan Mahendra KadiaCaitlin R RauschKen FurudateNaval G DaverYesid AlvaradoMaro OhanianKoiji SasakiNicholas James ShortKoichi TakahashiMusa YilmazGuilin TangFarhad RavandiHagop M KantarjianCourtney D Di NardoMarina Y KonoplevaPublished in: Cancer (2021)
Patients with TP53mut AML have lower response rates and shorter survival with DEC10-VEN.